• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

完成时间窗对癌症患者健康相关生活质量结局分析的影响。

Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients.

机构信息

Department of Quality of Life, European Organisation for Research and Treatment of Cancer Headquarters (EORTC HQ), Brussels, Belgium.

出版信息

Ann Oncol. 2013 Jan;24(1):231-7. doi: 10.1093/annonc/mds220. Epub 2012 Aug 30.

DOI:10.1093/annonc/mds220
PMID:22935549
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3525133/
Abstract

BACKGROUND

We examined if cancer patients' health-related quality of life (HRQoL) scores on the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 are affected by the specific time point, before or during treatment, at which the questionnaire is completed, and whether this could bias the overall treatment comparison analyses.

PATIENTS AND METHODS

A 'completion-time window' variable was created on three closed EORTC randomised control trials in lung (non-small cell lung cancer, NSCLC) and colorectal cancer (CRC) to indicate when the QLQ-30 was completed relative to chemotherapy cycle dates, defined as 'before', 'on' and 'after'. HRQoL mean scores were calculated using a linear mixed model.

RESULTS

Statistically significant differences (P<0.05) were observed on 6 and 5 scales for 'on' and 'after' comparisons in the NSCLC and two-group CRC trial, respectively. As for the three-group CRC trial, several statistical differences were observed in the 'before' to 'on' and the 'on' to 'after' comparisons. For all three trials, including the 'completion-time window' variable in the model resulted in a better fit, but no substantial changes in the treatment effects were noted.

CONCLUSIONS

We showed that considering the exact timing of completion within specified windows resulted in statistical and potentially clinically significant differences, but it did not alter the conclusions of treatment comparison in these studies.

摘要

背景

我们研究了癌症患者在欧洲癌症研究与治疗组织(EORTC)QLQ-C30 上的健康相关生活质量(HRQoL)评分是否受到完成问卷的特定时间点(治疗前或治疗期间)的影响,以及这是否会影响总体治疗比较分析。

方法

我们在三个关于肺癌(非小细胞肺癌,NSCLC)和结直肠癌(CRC)的 EORTC 随机对照试验中创建了一个“完成时间窗”变量,以指示 QLQ-30 相对于化疗周期日期的完成时间,定义为“之前”、“期间”和“之后”。使用线性混合模型计算 HRQoL 平均得分。

结果

在 NSCLC 和两组 CRC 试验中,“期间”和“之后”比较的 6 个和 5 个量表上观察到统计学显著差异(P<0.05)。对于三组 CRC 试验,在“之前”到“期间”和“期间”到“之后”的比较中观察到了几个统计学差异。对于所有三个试验,在模型中包含“完成时间窗”变量导致了更好的拟合,但治疗效果没有实质性变化。

结论

我们表明,考虑到特定时间窗内的确切完成时间会导致统计学和潜在临床显著差异,但这并未改变这些研究中治疗比较的结论。

相似文献

1
Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients.完成时间窗对癌症患者健康相关生活质量结局分析的影响。
Ann Oncol. 2013 Jan;24(1):231-7. doi: 10.1093/annonc/mds220. Epub 2012 Aug 30.
2
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.微卫星不稳定高或错配修复缺陷转移性结直肠癌患者一线帕博利珠单抗与化疗治疗的健康相关生活质量(KEYNOTE-177):一项开放标签、随机、III 期试验。
Lancet Oncol. 2021 May;22(5):665-677. doi: 10.1016/S1470-2045(21)00064-4. Epub 2021 Apr 1.
3
Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.解读参与随机对照试验的肺癌患者 EORTC QLQ-C30 健康相关生活质量评分的最小有意义差异。
Support Care Cancer. 2011 Nov;19(11):1753-60. doi: 10.1007/s00520-010-1016-5. Epub 2010 Oct 1.
4
Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer.不可切除局部晚期非小细胞肺癌长期生存者的健康相关生活质量。
Radiat Oncol. 2017 Dec 2;12(1):195. doi: 10.1186/s13014-017-0909-6.
5
Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy.在接受化疗的晚期结直肠癌患者中解释 EORTC QLQ-C30 的最小有意义差异。
Colorectal Dis. 2020 Dec;22(12):2278-2287. doi: 10.1111/codi.15295. Epub 2020 Aug 28.
6
Health-related quality of life in advanced non-small cell lung cancer: correlates and comparisons to normative data.晚期非小细胞肺癌患者的健康相关生活质量:相关性及与常模数据的比较。
Eur J Cancer Care (Engl). 2012 Sep;21(5):642-9. doi: 10.1111/j.1365-2354.2012.01346.x. Epub 2012 Apr 23.
7
Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients.生活质量测量指标(欧洲癌症研究与治疗组织生活质量问卷核心30条目版和简明健康状况调查量表)作为晚期结直肠癌和肺癌患者生存情况的预测指标
Palliat Support Care. 2009 Sep;7(3):289-97. doi: 10.1017/S1478951509990216.
8
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.帕博利珠单抗对比化疗用于晚期 PD-L1 阳性 NSCLC 的疗效及安全性(KEYNOTE-024):一项多中心、国际、随机、开放标签的 3 期临床试验。
Lancet Oncol. 2017 Dec;18(12):1600-1609. doi: 10.1016/S1470-2045(17)30690-3. Epub 2017 Nov 9.
9
How quality of life data contribute to our understanding of cancer patients' experiences? A study of patients with lung cancer.生活质量数据如何有助于我们理解癌症患者的经历?一项针对肺癌患者的研究。
Qual Life Res. 2003 Mar;12(2):157-66. doi: 10.1023/a:1022232624891.
10
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).在 III 期随机临床试验中,brigatinib 对比crizotinib 治疗初治晚期 ALK 阳性非小细胞肺癌(ALTA-1L)患者的健康相关生活质量。
Lung Cancer. 2021 May;155:68-77. doi: 10.1016/j.lungcan.2021.03.005. Epub 2021 Mar 9.

引用本文的文献

1
The Impact of the Timing of Health-Related Quality of Life Assessments on the Actual Results in Glioma Patients: A Randomized Prospective Study.健康相关生活质量评估时间对胶质瘤患者实际结果的影响:一项随机前瞻性研究。
Cancers (Basel). 2020 Aug 5;12(8):2172. doi: 10.3390/cancers12082172.
2
Quality of life of patients with gastrointestinal cancers undergoing chemotherapy.胃肠道癌症化疗患者的生活质量。
Qual Life Res. 2018 Jul;27(7):1865-1876. doi: 10.1007/s11136-018-1860-1. Epub 2018 Apr 21.
3
Joint modeling of longitudinal health-related quality of life data and survival.纵向健康相关生活质量数据与生存情况的联合建模
Qual Life Res. 2015 Apr;24(4):795-804. doi: 10.1007/s11136-014-0821-6. Epub 2014 Oct 14.
4
Assessing quality of life on the day of chemotherapy administration underestimates patients' true symptom burden.在化疗给药当天评估生活质量会低估患者真正的症状负担。
BMC Cancer. 2014 Oct 10;14:758. doi: 10.1186/1471-2407-14-758.
5
Using patient-reported outcome measures for improved decision-making in patients with gastrointestinal cancer - the last clinical frontier in surgical oncology?利用患者报告的结局测量指标改善胃肠癌患者的决策——外科肿瘤学的最后临床前沿?
Front Oncol. 2013 Jun 14;3:157. doi: 10.3389/fonc.2013.00157. eCollection 2013.
6
Health-related quality of life in patients with brain tumors: limitations and additional outcome measures.脑肿瘤患者的健康相关生活质量:局限性和额外的结局测量指标。
Curr Neurol Neurosci Rep. 2013 Jul;13(7):359. doi: 10.1007/s11910-013-0359-y.

本文引用的文献

1
Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer.EORTC QLQ-C30、QLQ-CR38 和 FACT-C 生活质量问卷在结直肠癌患者中的反应性。
Health Qual Life Outcomes. 2011 Aug 22;9:70. doi: 10.1186/1477-7525-9-70.
2
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.转移性结直肠癌患者接受每周大剂量输注氟尿嘧啶加亚叶酸,联合或不联合伊立替康的III期研究:欧洲癌症研究与治疗组织胃肠癌研究组40986研究
J Clin Oncol. 2005 Aug 1;23(22):4856-65. doi: 10.1200/JCO.2005.05.546. Epub 2005 Jun 6.
3
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial.局部晚期乳腺癌幸存者的健康相关生活质量:一项国际随机对照III期试验。
Lancet Oncol. 2005 May;6(5):287-94. doi: 10.1016/S1470-2045(05)70100-5.
4
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.两种基于顺铂的方案与紫杉醇加吉西他滨治疗晚期非小细胞肺癌的三臂随机研究:欧洲癌症研究与治疗组织肺癌组的III期试验——EORTC 08975
J Clin Oncol. 2003 Nov 1;21(21):3909-17. doi: 10.1200/JCO.2003.03.195.
5
Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy.化疗期间恶心呕吐对癌症患者生活质量的影响。
Health Qual Life Outcomes. 2003 Sep 17;1:46. doi: 10.1186/1477-7525-1-46.
6
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.高剂量氟尿嘧啶每周24小时输注联合或不联合亚叶酸钙与氟尿嘧啶推注加亚叶酸钙治疗晚期结直肠癌的随机III期研究:欧洲癌症研究与治疗组织胃肠癌研究组40952研究
J Clin Oncol. 2003 Oct 15;21(20):3721-8. doi: 10.1200/JCO.2003.11.122. Epub 2003 Sep 8.
7
Quality of life and utility in irradiated laryngeal cancer patients.喉癌放疗患者的生活质量与效用值
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):875-81. doi: 10.1016/s0360-3016(00)00560-5.
8
Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study.生活质量数据分析中的汇总指标与统计学方法:来自欧洲癌症研究与治疗组织-加拿大国立癌症研究所-瑞士癌症研究协会局部晚期乳腺癌研究的实例
Eur J Cancer. 2000 May;36(7):834-44. doi: 10.1016/s0959-8049(00)00056-3.
9
A clinical model for quality of life assessment in cancer patients receiving chemotherapy.一种用于评估接受化疗的癌症患者生活质量的临床模型。
Ann Oncol. 2000 Jan;11(1):23-30. doi: 10.1023/a:1008394107982.
10
Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial.改变临床试验中给药时间和生活质量评估时间范围的影响:以一项大型止吐试验中使用欧洲癌症研究与治疗组织核心生活质量问卷(EORTC QLQ-C30)为例
Qual Life Res. 1998 Apr;7(3):273-8. doi: 10.1023/a:1024954518241.